



BioLayer Corporation Limited

07 March 2008

Company Announcements Office
Australian Securities Exchange
Level 6, 20 Bridge Street
Sydney NSW 2000

RIGHTS ISSUE UPDATE

As a result of on-going volatility in financial markets and given the fall in the S&P/ASX index since 1 February 2008, under the terms of the underwriting agreement entered into in relation to the Company's 1 for 1 rights issue (previously announced to the market) the underwriter now has the right to terminate the Underwriting Agreement.

The Company wishes to advise that the underwriter (Transocean Securities Pty Ltd) remains supportive of the rights issue and has indicated that, while it will continue to monitor market conditions, it has no present intent to terminate the Underwriting Agreement.

David Beins
Managing Director & CEO
BioLayer Corporation Limited

About BioLayer:

BioLayer Corporation is an Australian company specializing in the design and assembly of multi-component coatings for the solid phase of immunoassay and the use of those coatings in biomarker development. BioLayer's proprietary coatings bind, orient and protect proteins such as antibodies in specific ways that enhance functionality. This results in dramatically improved immunoassay performance such as better sensitivity, and cost savings such as batch-to-batch reproducibility. BioLayer applies its coatings to develop novel biomarkers for a range of diseases such as Alzheimer's. BioLayer works with many types of solid phase materials and formats, like beads of different kinds, membranes and plates. For more information, visit www.bio-layer.com.

BioLayer Corporation Limited ABN 75 070 028 625
Unit 4, 26 Brandl Street, Eight Mile Plains QLD 4113
Phone 07 3219 0085 Fax 07 3219 0553 Email contact@biolayercorp.com
Web www.biolayercorp.com